Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes

Diabetologia

Volumn 57, Issue 8, 2014, Pages 1664-1673

  Favaro, Enrica ^a   Carpanetto, Andrea ^a   Lamorte, Sara ^a   Fusco, Alberto ^a   Caorsi, Cristiana ^b   Deregibus, Maria C ^a   Bruno, Stefania ^b   Amoroso, Antonio ^a   Giovarelli, Mirella ^b   Porta, Massimo ^a   Perin, Paolo Cavallo ^a   Tetta, Ciro ^b,c   Camussi, Giovanni ^a   Zanone, Maria M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Fresenius Medical Care   (Germany)

Author keywords

Glutamic acid decarboxylase; Mesenchymal stem cells; Microvesicles; miR 21; T cells; Type 1 diabetes

Indexed keywords

GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE; GLUTAMATE DECARBOXYLASE;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CYTOKINE RELEASE; DIABETIC PATIENT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; INTERNALIZATION; MALE; MESENCHYMAL STEM CELL; PANCREAS ISLET; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TH2 CELL; ULTRACENTRIFUGATION; YOUNG ADULT; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM;

ADULT; CYTOKINES; DIABETES MELLITUS, TYPE 1; DINOPROSTONE; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84904751710     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3262-4     Document Type: Article

References (49)

1. Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221-229 (Pubitemid 32718550)
2. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M (2010) Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Expert Immunol 160:176-184
3. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC (2005) Effects of allogenic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 24:458-463 (Pubitemid 40994557)
4. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood 106:1755-1761 (Pubitemid 41208591)
5. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822 (Pubitemid 40223708)
6. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH (2008) Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57:1759-1767
7. Zanone MM, Favaro E, Miceli I et al (2010) Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. J Clin Endocrinol Metab 95:3788-3797
8. Ezquer F, Ezquer M, Contador D, Ricca M, Simon V, Conget P (2012) The antidiabetic effect ofmesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells 30:1664-1674
9. Fiorina P, Voltarelli J, Zavazava N (2011) Immunological application of stem cells in type 1 diabetes. Endocr Rev 32:725-754
10. Li YP, Paczesny S, Lauret E, Poirault S et al (2008) Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 180:1598-1608
11. Selmani Z, Naji A, Zidi I et al (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 26:212-222
12. Collino F, Deregibus MC, Bruno S et al (2010) Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 27:1-15
13. Lai RC, Chen TS, Lim SK (2011) Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med 6:481-492
14. Gatti S, Bruno S, Deregibus MC et al (2011) Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 26:1474-1483
15. Bruno S, Grange C, Deregibus MC et al (2009) Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 20:1053-1067
16. Timmers L, Lim SK, Arslan F et al (2007) Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cells Res 1:129-137
17. Ratajczak MZ, Kucia M, Jadczyk T et al (2012) Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies? Leukemia 26:1166-1173
18. Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9:581-593
19. American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(Suppl 1):S62-S67
20. Bruno S, Grange C, Collino F et al (2012) Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One 7:1-11
21. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G (2004) Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 14:1035-1041
22. Christopeit M, Schendel M, Föll J, Müller LP, Keysser G, Behre G (2008) Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 22:1062-1064 (Pubitemid 351689891)
23. Lee RH, Seo MJ, Reger RL et al (2006) Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 103:17438-17443 (Pubitemid 44788987)
24. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S (2007) Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells 25:2837-2844 (Pubitemid 350127868)
25. Zhao M, Amiel SA, Ajami S et al (2008) Amelioration of streptozotocin-induced diabetes in mice with cells derived from human marrow stromal cells. PLoS ONE 3:1-9
26. Reading JL, Yang JHM, Sabbah S et al (2013) Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity. J Immunol 190:4542-4552
27. Tan J, Wu W, Xu X et al (2012) Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307:1169-1177
28. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736
29. Arif S, Moore F, Marks K et al (2011) Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes 60:2112-2119
30. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111:1327-1333 (Pubitemid 351213419)
31. Pap E, Pállinger E, Falus A (2011) The role of membrane vesicles in tumorigenesis. Crit Rev Oncol Hematol 79:213-223
32. Di Nicola M, Carlo-Stella C, Magni M et al (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843 (Pubitemid 34534559)
33. Chen W, Frank ME, Jin W, Wahl SM (2001) TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14:715-725 (Pubitemid 32592419)
34. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P (2010) Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 184:5885-5894
35. Horwitz DA, Zheng SG, Gray JD (2008) Natural and TGF-beta-induced Foxp3(+)CD4(+)CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol 29:429-435
36. Luo X, Yang H, Kim IS et al (2005) Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 79:1091-1096 (Pubitemid 40664003)
37. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA (2004) TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+ CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 101:4572-4577 (Pubitemid 38437452)
38. Butz H, Rácz K, Hunyady L, Patocs A (2012) Crosstalk between TGF-β signaling and the microRNA machinery. Trends Pharmacol Sci 33:382-393
39. Fiorina P, Jurewicz M, Augello A et al (2009) Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183:993-1000
40. Madec AM, Mallone R, Afonso G et al (2009) Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52:1391-1399
41. Boumaza I, Srinivasan S, Witt WT et al (2009) Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 32:33-42
42. Augello A, Tasso R, Negrini SM et al (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35:1482-1490 (Pubitemid 40691430)
43. Jurewicz M, Yang S, Augello A et al (2010) Congenic mesenchymal stem cell therapy reverse hyperglycemia in experimental type 1 diabetes. Diabetes 59:3139-3147
44. Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K (2012) Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett 147:47-54
45. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I (2008)Human CD25 high Foxp3 pos regulatory Tcells differentiate into IL-17-producing cells. Blood 112:2340-2352
46. Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H (2010) Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302-312
47. Kristiansen OP, Mandrup-Poulsen T (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54(Suppl 2):S114-S124
48. Staeva TP, Chatenoud L, Insel R, Atkinson MA (2013) Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 62:9-17
49. Sundin M, Barrett AJ, Ringdén O et al (2009) HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 32:755-764